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plays an important role in the ﬁrst step of the reverse cholesterol transport system.
Aims.— We studied the association of four polymorphisms in the ABCA1 gene (G1051A, G2706A,
G2868A and —565C/T) with lipid proﬁle and coronary artery disease.
Methods.— Overall, 316 Tunisian patients underwent coronary angiography. Genotyping was
performed using polymerase chain reaction-restriction fragment length polymorphism analysis.
Lipid and apolipoprotein concentrations were measured.
Abbreviations: ABCA1, adenosine triphosphate-binding cassette transporter A1; ApoAI, apolipoprotein AI; ApoB, apolipoprotein B; CI,
onﬁdence interval; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ORs, odds ratios; SCS,
igniﬁcant coronary stenosis.
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Results.— Only carriers of the G2706A allele were associated with a decreased risk of signiﬁ-
cant stenosis (odds ratio [OR] 0.66, 95% conﬁdence interval [CI] 0.22—0.92, p = 0.029), without
pronounced effects on high-density lipoprotein (HDL) cholesterol. This protective effect was
signiﬁcant in smokers and diabetes. Carriers of the G1051A allele were associated only with
increased concentrations of HDL cholesterol (p = 0.032). G2868A and —565C/T did not show any
association with lipids or risk of signiﬁcant stenosis. When ABCA1 polymorphisms were combined
in haplotypes possessing G1051A, G2706A, G2868A and —565C/T, (AAGC) seemed to be most pro-
tective against signiﬁcant stenosis (OR 0.5, 95% CI 0.29—0.96, p = 0.048) whereas (GGAT) was
probably the most atherogenic (OR 1.26, 95% CI 1.03—1.56, p = 0.025).
Conclusion.— Only the G2706A allele seems to be associated with a reduced risk of signiﬁ-
cant stenosis without important modiﬁcation of HDL-cholesterol concentration, and appears to
be more protective for smokers and diabetic patients. We found that (AAGC) seems to be a
protective haplotype whereas (GGAT) has an atherogenic effect in a Tunisian population.
© 2010 Elsevier Masson SAS. All rights reserved.
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Résumé
Contexte.— Le transporteur adenosine triphosphate-binding cassette A1 (ABCA1) joue un rôle
important dans le transport inverse du cholestérol.
Objectifs.— Étude de l’association de quatre polymorphismes (G1051A, G2706A, G2868A,
—565C/T) au niveau du gène ABCA1 avec le proﬁl lipidique et la sténose coronaire dans notre
population d’étude.
Méthodes.— Nous avons recruté 316 patients, documentés par coronarographie. Le génotypage
a été réalisé par polymérisation en chaîne suivie de digestion par enzymes de restriction. Les
paramètres lipidiques et apolipoprotéiques ont été dosés.
Résultats.— Seulement l’allèle G2706A a été associé à une diminution du risque coronarien (OR
0,658, 95 %IC 0,22—0,92, p = 0,029), sans effets prononcés sur HDL-C. Cet effet protecteur a été
surtout signiﬁcatif chez les fumeurs et les diabétiques. Les polymorphismes G2868A et —565C/T
n’ont montré aucune association avec le proﬁl lipidique ou avec la sténose coronaire. L’allèle
G1051A a été seulement associé à une augmentation de HDL-C (p = 0,032). En combinant les
polymorphismes ABCA1 (G1051A, G2706A, G2868A, —565C/T) en haplotypes (AAGC), semble
être l’haplotype le plus protecteur contre la SCS (OR 0,5, 95 %IC 0,29—0,96 ; p = 0,048) tandis
que (GGAT) serait le plus athérogène (OR 1,26, 95 %IC 1,03—1,56, p = 0,025).
Conclusion.— L’allèle G2706A semble être associé au risque réduit de sténose coronaire sans
modiﬁcation importante de HDL-C. Cet effet protecteur est plus prononcé chez les fumeurs et
les diabétiques. Parmi, les AAGC semblent être protecteur et (GGAT) serait athérogène dans
Tous droits réservés.
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Background
Low concentrations of plasma high-density lipoprotein
cholesterol (HDL-C) are associated with an increased risk of
atherosclerotic complications [1]. An important mechanism
underlying the antiatherogenic properties of high-density
lipoprotein is its role in reverse cholesterol transport,
the pathway that facilitates the transfer of cholesterol
from peripheral tissues back to the liver [2]. The adeno-
sine triphosphate-binding cassette transporter A1 (ABCA1)
has been identiﬁed as the mediator of the initial step
of reverse cholesterol transport because it facilitates the
efﬂux of phospholipids and cholesterol from peripheral cells
to lipid-free apolipoprotein AI (ApoAI), creating nascent
high-density lipoprotein particles [3]. The human gene for
ABCA1 is composed of 50 exons spanning 149 kb of genomic
sequence. It has been mapped to the region q31 of chro-
mosome 9 [4] and encodes a 2261 amino acid protein with
a predicted molecular weight of 220 kDa. Human ABCA1 is
a
[
s
irimarily expressed in placenta, liver, lung, adrenal glands
nd foetal tissues [5].
Although HDL-C concentration is strongly inﬂuenced
y environmental factors [6], research has been focused
ncreasingly on genetic causes leading to reduced HDL-C.
eﬁciency of ABCA1 has been identiﬁed as the molecu-
ar cause of Tangier disease, a rare condition with very
ow concentrations of HDL-C, excessive accumulation of
holesteryl esters in tissue macrophages and the reticu-
oendothelial system, with an increased risk of premature
oronary disease [7]. Many common genetic variations of
BCA1 have been reported to be associated with variations
n serum lipid concentrations (particularly HDL-C) and may
lso be associated with coronary artery disease risk, but this
ssociation is still controversial among several populations
8—11].To our knowledge, there are no published data on the
creening of the ABCA1 gene or on its association with signif-
cant coronary stenosis (SCS) among the Tunisian population.
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concentrations, signiﬁcantly higher triglyceride concentra-32
In this study, four variants identiﬁed in ABCA1
ene (G1051A [rs2230806], G2706A [rs2066718], G2868A
rs4149312] and —565C/T [rs2422493]) were screened in a
unisian population.
aterials and methods
tudy population
ampling procedures for this study have been described
reviously in detail [12]. Brieﬂy, the study comprised 316
atients who underwent coronary angiography because of
yocardial infarction (n = 113), angina (n = 169), thoracic
ain (n = 18) or heart failure (n = 16) in the Cardiology
epartment at Sahloul University Hospital, Sousse, Tunisia.
atients were subdivided into two groups: those with SCS
nd those without SCS. SCS patients were those who had
igniﬁcant coronary artery stenosis, which was deﬁned as
luminal narrowing of ≥ 50% in at least one major coro-
ary artery. Patients without SCS were those without any
igniﬁcant coronary artery stenosis (< 50%).
Data on lifestyle factors were collected using an
nterviewer-administered questionnaire, which included
uestions about personal history, presence of disease, drug
ntake (if any), cigarette smoking and alcohol consumption.
atients taking lipid-lowering drugs were excluded. Diabetes
ellitus was deﬁned as fasting glucose > 7 mmol/L or cur-
ently receiving antidiabetic medication. The smoking status
f an individual was assigned ‘yes’ if they were smoking cur-
ently or had given up < 3 months previously. Hypertension
as deﬁned as blood pressure > 140/90 mmHg or currently
n antihypertensive medication. Dyslipidaemia was deﬁned
s low-density lipoprotein cholesterol (LDL-C) concentra-
ion ≥ 4.1 mmol/L and/or HDL-C concentration ≤ 1 mmol/L
nd/or triglyceride concentration ≥ 1.71 mmol/L. Informed
onsent was taken from all the participants. The study was
pproved by the local medical ethics committee.
easurement of serum lipids and
polipoproteins
fter overnight fasting and before coronary angiogra-
hy, blood was collected from each subject. Serum total
holesterol, triglyceride and HDL-C concentrations were
etermined by a standard method using the Synchrom
X7 Clinical System (Beckman, Fullerton, CA, USA). LDL-C
oncentration was calculated using the Friedewald for-
ula [13] when the triglyceride concentration was < 4
mol/L; otherwise, LDL-C concentration was measured
irectly using the Synchrom CX7 Clinical System (Beck-
an, Fullerton, CA, USA). Serum ApoAI and apolipoprotein
(ApoB) concentrations were determined using the IMMAGE
mmunochemistry System (Beckman, Fullerton, CA, USA),
ased on immunonephelometric quantitation. ApoB/ApoAI
nd total cholesterol/HDL-C ratios were calculated. We con-
idered elevation of these atherogenicity ratios as > 0.86 and
4.5, respectively, and hypoApoAI as ≤ 0.9 g/L.NA extraction and ABCA1 genotyping
enomic DNA was extracted from ethylenediaminete-
raacetic acid-treated whole blood samples using a
t
t
v
c
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alting-out method [14]. The genotypes for each ABCA1
olymorphism (G1051A [R219K], G2706A [V771M], G2868A
V825I] and —565C/T [—477C/T]) were determined by
olymerase chain reaction-restriction fragment length
olymorphism analysis. The G1051A and —565C/T poly-
orphisms were genotyped following Assmann and Nofer
2]; the G2706A and G2868A polymorphisms were geno-
yped as described by Miller and Miller [1]. The polymerase
hain reaction was carried out using a deoxyribonucleic
cid thermal cycler (LP×2 Thermal Cycler, Thermo Electron
orporation, Milford, NE, USA). After initial denatura-
ion at 95 ◦C for 5min, the polymerase chain reaction
as carried out for 35 cycles, each cycle comprising
denaturation at 95 ◦C for 45 s, an annealing tem-
erature as described previously [1,2] for 45 s and
2 ◦C for 45 s, with a ﬁnal extension time of 7min at
2 ◦C. Shortly, each polymerase chain reaction product of
1051A, G2706A, G2868A and —565C/T polymorphisms was
igested using StyI (2U), BsaAI (2U), BsaI (3U) and AciI
2U), respectively. Polymerase chain reaction products and
he digested products were resolved by 2% agarose gel
lectrophoresis and visualized by ethidium bromide stain-
ng.
tatistical analysis
tatistical analysis was performed by SPSS 16.0 for Win-
ows. The biological variables were compared by one-way
nalysis of variance then by Student’s t-test or Fisher’s
xact test and their values were reported as means ± stan-
ard deviations. A chi-square analysis was performed to
etermine the Hardy—Weinberg equilibrium of the polymor-
hism studied in both groups with one degree of freedom.
enotype and allele frequencies were compared by a chi-
quare test. Pairwise linkage disequilibrium coefﬁcients
ere expressed as D’, which is the ratio of unstandardized
oefﬁcient to its minimal/maximal value, and estimated
sing a single nucleotide polymorphism analyser programme
15]. Odds ratios (ORs) were calculated as a measure
f the association of the each ABCA1 genotype with the
henotype. For each OR, two-tailed p values and 95%
onﬁdence intervals (CIs) were calculated; p was consid-
red to be signiﬁcant when it was < 0.05. Adjusted ORs
or potential confounders were determined using logis-
ic regression analysis and corresponding p values were
eported.
esults
opulation characteristics
linical and biochemical characteristics of the study pop-
lation are given in Table 1. Patients with SCS had
igniﬁcantly lower HDL-C (p = 0.040) and ApoAI (p = 0.009)ions (p = 0.022) and a higher ApoB/ApoAI ratio (p = 0.036)
han patients without SCS. All variables with a p
alue < 0.25 between the two studied groups were
onsidered as confounding factors for further OR adjust-
ent.
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Table 1 Clinical and biochemical characteristics of the study population.
Characteristic With SCS (n = 212) Without SCS (n = 104) p
Sex ratio (men/women) 1.97 1.26 0.010
Age (years) 60.6 ± 10.6 59.4 ± 11.9 0.38
Smoker 120 (56.6) 47 (45.2) 0.013
Diabetic 73 (34.4) 23 (22.1) 0.001
Hypertension 97 (45.7) 46 (44.2) 0.35
History of myocardial infarction 91 (42.9) 13 (12.5) < 0.001
Dyslipidaemia 33 (15.6) 9 (8.6) 0.027
Total cholesterol (mmol/L) 5.029 ± 1.192 5.025 ± 1.087 0.970
Triglyceride (mmol/L) 1.614 ± 1.117 1.340 ± 0.647 0.022
HDL-C (mmol/L) 0.961 ± 0.283 1.030 ± 0.276 0.040
LDL-C (mmol/L) 3.440 ± 1.167 3.330 ± 1.039 0.37
ApoAI (g/L) 1.160 ± 0.379 1.290 ± 0.437 0.009
ApoB (g/L) 1.153 ± 0.376 1.110 ± 0.413 0.46
ApoB/ApoAI 1.057 ± 0.493 0.920 ± 0.290 0.036
Total cholesterol/HDL-C 5.630 ± 2.040 5.410 ± 1.890 0.43
prot
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AData are mean ± standard deviation or number (%). ApoAI: apolipo
HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density li
ABCA1 genotypes
The prevalence of the four ABCA1 polymorphisms (G1051A,
G2706A, G2868A and —565C/T) was evaluated in 316 sub-
jects. Each of these polymorphisms was found to be in the
Hardy—Weinberg equilibrium. Genotype and allele frequen-
cies are shown in Table 2. The prevalence of homozygous
individuals for the G2706 allele was signiﬁcantly higher
(p = 0.009) in the SCS group. No mutated genotype for this
polymorphism was found in the group without SCS. No sig-
niﬁcant difference was observed in genotype frequencies
between the two groups for the other three polymorphisms.
No allele frequency difference was observed between
patients with versus without SCS for any polymorphism.
Associations between ABCA1 polymorphisms
and serum lipid concentrations
The lipid proﬁle of the studied polymorphisms was inves-
tigated according to the genotype distributions. Only
individuals with the 1051AA genotype and A allele carriers
p
T
p
i
Table 2 ABCA1 genotypes and allele frequencies among patie
ABCA1 SNPs With SCS
(n = 212)
Without SC
(n = 104)
G1051A GG GA AA GG GA AA
% 40 47.7 12.3 35.6 50.9 13
G2706A GG GA AA GG GA AA
% 91 8.5 0.5 80 20 0
G2868A GG GA AA GG GA AA
% 76.9 22.6 0.5 79.8 19.2 1
—565C\T CC CT TT CC CT TT
% 24.5 52.9 22.6 27.9 54.8 17
ABCA1: adenosine triphosphate-binding cassette transporter A1; SCS: siein AI; ApoB: apolipoprotein B; SCS: signiﬁcant coronary stenosis;
tein cholesterol.
genotypes GA+AA) had a signiﬁcantly higher mean HDL-C
oncentration than individuals with the 1051GG genotype
1.08 ± 0.35, p = 0.042 and 1.11 ± 0.34, p = 0.032, respec-
ively, vs 0.93 ± 0.37 in the study population). There were
o signiﬁcant differences in mean serum HDL-C concentra-
ions in either genotype of the —565C/T, G2706A and G2868A
olymorphisms. No statistically signiﬁcant differences in
ther lipids variables were seen in any genotype.
In addition, A allele carriers (genotypes GA+AA) of the
2706A polymorphism seemed to have a low risk of hypo-
DLaemia (OR 0.39, 95% CI 0.19—0.81, p = 0.012). The
isk of atherogenicity ratio elevation, hypoHDLaemia and
ypoApoAI associated with the four polymorphisms was not
igniﬁcant.
ssociations of ABCA1 polymorphisms with the
resence of stenosis
able 3 shows the ORs for signiﬁcant stenosis for the four
olymorphisms of ABCA1. After adjustment for confound-
ng variables, only the carriers of the G2706A allele were
nts with and without SCS in a Tunisian population.
S p With SCS Without SCS p
0.68 A-allele frequency 0.95
.5 0.64 0.61
0.009 A-allele frequency 0.89
0.05 0.1
0.77 A-allele frequency 0.98
0.12 0.11
0.60 T-allele frequency 0.95
.3 0.49 0.45
gniﬁcant coronary stenosis; SNP: single nucleotide polymorphism.
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Table 3 Odds ratios for signiﬁcant stenosis according to ABCA1 polymorphisms.
Polymorphisms Crude ORs Adjusted ORsa
OR 95% CI pb OR 95% CI pb
G1051A GG 1 — —0.23 1 — —
GA+AA 0.81 —0.50—1.30 0.74 —0.44—1.25 —0.25
G2706A GG 1 — —0.004 1 — —
GA+AA 0.59 —0.19—0.75 0.66 —0.22—0.92 —0.029
G2868A GG 1 — —0.34 1 — —
GA+AA 1.17 —0.66—2.07 1.19 —0.64—2.18 —0.57
—565C/T CC 1 — —0.33 1 — —
CT+TT 1.16 —0.68—1.98 1.28 —0.72—2.28 —0.39
ABCA1: adenosine triphosphate-binding cassette transporter A1; CI: conﬁdence interval; OR: odds ratio.
a Adjusted for age, sex, diabetes, smoking status, hypertension, dyslipidaemia.
b All p values are calculated by comparison with wild type genotypes.
Table 4 Odds ratios for signiﬁcant stenosis according to smoking status.
Polymorphisms Smokers Non-smokers
ORa 95% CI pb ORa 95% CI pb
G1051A GG 1 — —0.56 1 — —
GA+AA 0.97 —0.44—2.13 0.69 —0.37—1.27 —0.15
G2706A GG 1 — —0.021 1 — —
GA+AA 0.48 —0.09—0.83 0.75 —0.18—1.07 —0.055
G2868A GG 1 — —0.21 1 — —
GA+AA 1.72 —0.62—4.72 0.94 —0.46—1.91 —0.50
—565C/T CC 1 — —0.41 1 — —
CT+TT 1.21 —0.50—2.91 1.13 —0.56—2.25 —0.43
CI: conﬁdence interval; OR: odds ratio.
pes.
a
0
o
p
i
da Adjusted for age, sex, diabetes, hypertension, dyslipidaemia.
b All p values are calculated by comparison with wild type genoty
ssociated with a decreased risk of signiﬁcant stenosis (OR
.66, 95% CI 0.22—0.92, p = 0.029), although the frequency
f the G2706A allele was low. The interaction of polymor-
hisms with other risk factors was studied, and a signiﬁcant
nteraction of the G2706A polymorphism with smoking and
s
f
(
t
Table 5 Odds ratios for signiﬁcant stenosis according to diabe
Polymorphisms Diabetes
ORa 95% CI
G1051A GG 1 —
GA+AA 0.83 —0.34—1.98
G2706A GG 1 —
GA+AA 0.53 —0.03—0.86
G2868A GG 1 —
GA+AA 1.15 —0.44—3.00
—565C/T CC 1 —
CT+TT 0.78 —0.28—2.13
CI: conﬁdence interval; OR: odds ratio.
a Adjusted for age, sex, smoking status, hypertension, dyslipidaemia.
b All p values are calculated by comparison with wild type genotypes.iabetes was noted. In fact, in the binary logistic regres-
ion model, we found Exp(B) 1. 22, CI 1.02—1.73 (p = 0.044)
or smoking by G2706A and Exp(B) 1. 62, CI 1.058—2.485
p = 0.026) for diabetes by G2706A, hence the study popula-
ion was stratiﬁed according to smoking and diabetes status.
tes.
No diabetes
pb ORa 95% CI pb
—0.67 1 — —
0.93 —0.46—1.87 —0.84
—0.007 1 — —
0.75 —0.26—1.59 —0.35
—0.77 1 — —
1.33 —0.62—2.84 —0.46
—0.63 1 — —
1.42 —0.64—3.16 —0.38
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The protective effect of G2706A seemed to be more
signiﬁcant in smokers than non-smokers (OR 0.48, 95% CI
0.10—0.83, p = 0.021) and in those with versus without dia-
betes (OR 0.53, 95% CI 0.03—0.86, p = 0.007) (Tables 4 and 5).
No signiﬁcant association was observed with the risk of
signiﬁcant stenosis for the −565C/T polymorphism or the
two polymorphisms in the coding region (G1051A, G2868A),
neither in study population nor according to smoking or dia-
betic status.
Linkage disequilibrium and haplotype analysis
The G1051A polymorphism was in signiﬁcant linkage dise-
quilibrium with G2706A (D’ 0.27, p = 0.0074) and G2868A (D’
—0.28, p = 0.039). When the four ABCA1 polymorphisms were
combined, the haplotype model (AAGC), possessing G1051A,
G2706A, G2868A and —565C/T polymorphisms, seemed to be
the most protective. In fact, it occurred more frequently in
patients without SCS than in the SCS group (0.079 vs 0.030).
The haplotype model (GGAT) occurred more frequently in
SCS patients than in those without SCS (0.044 vs 0.016).
On haplotype analysis, after adjustment for confound-
ing factors, the (AAGC) haplotype consistently showed
the lowest risk of signiﬁcant stenosis compared with the
wild haplotype (possessing all common alleles: GGGC) (OR
0.5, 95% CI 0.29—0.96, p = 0.048). The (GGAT) haplotype
increased the risk of signiﬁcant stenosis (OR 1.26, 95% CI
1.03—1.56, p = 0.025) compared with the wild haplotype.
The risks of hypoHDLaemia and hypoApoAI associated
with the (AAGC) haplotype were, respectively, OR 0.69,
95% CI 0.48—0.95 (p = 0.025) and OR 0.65, 95% CI 0.46—0.92
(p = 0.037). By comparison, the risks of hypoHDLaemia and
hypoApoAI associated with the (GGAT) haplotype were,
respectively, OR 1.26, 95% CI 0.76—2.10 (p = 0.36) and OR
0.7, 95% CI 0.48—1.02 (p = 0.06). None of the other haplo-
type combinations was associated with a signiﬁcant change
in HDL-C or ApoA1 concentrations, atherogenicity ratio ele-
vation or the risk of signiﬁcant stenosis.
Discussion
In the present study, we did not ﬁnd associations between
the ABCA1 variants studied and lipid proﬁle. Only the
AA genotype of the G1051A polymorphism was signiﬁ-
cantly associated with increased concentrations of HDL-C
(p = 0.042). The effect of the genotype on HDL-C remains
controversial, with some studies showing an association
between the genotype of these polymorphisms and higher
concentrations of HDL-C [16—20], and others showing no
effect [9,16,21—27].
The role of variation in ABCA1 in vascular risk remains
controversial [11,18,22,23,25,26,28]. Neither the −565C/T
single nucleotide polymorphism nor the two coding poly-
morphisms (G1051A, G2868A) were associated with a risk
of signiﬁcant stenosis in our study. We found that only
the G2706A variant was associated with a decreased risk
of signiﬁcant stenosis (OR 0.658, p = 0.029), without pro-
nounced effects on plasma lipids. Many studies are in
agreement with this result [17,20,29], although Frikke-
Schmidt et al. reported an increased risk of ischaemic
heart disease [18]. Emerging evidence suggests that ABCA1
s
1
p
s535
ene variants can exert phenotypic effects on atherosclero-
is, independent of changes in plasma lipid concentrations
9,11,17,23]. The association of G2706A polymorphisms with
igniﬁcant stenosis without a major change in the over-
ll HDL-C concentration suggests that this polymorphism
robably exerts its effects principally by HDL particle mod-
ﬁcation, with decreases in the relative fraction of large
DL particles that are believed to be cardioprotective, or
y modifying reverse cholesterol transport in macrophages.
n fact, it was reported that cholesterol efﬂux from cells in
he arterial wall that have the potential to transform into
oam cells — primarily macrophages — is directly relevant to
therosclerosis [30]. The absence of ABCA1 leads to signif-
cant changes in the morphology, properties and functional
ctivities of macrophages, resulting in increases in choles-
erol deposition and the response to chemotactic factors
31]. The selective inactivation of ABCA1 in the macrophages
f hyperlipidaemic mice leads to a marked increase in
therosclerosis and foam cell accumulation, demonstrating
he antiatherogenic properties of ABCA1, independent of
lasma lipid and HDL-C concentrations [32]. However, it has
een shown that the contribution of monocyte/macrophage
BCA1 to overall plasma HDL-C concentration is minimal
33].
Another result of our study is that only the A allele
f the G2706A variant appeared to be more protective
or smokers than non-smokers (OR 0.48, p = 0.021 vs OR
.74, p = 0.055). Smoking increases the rate of oxidation
f lipoprotein particles, and it might be possible that this
xidative stress can be alleviated in part through the ABCA1
athway, as ABCA1 has been reported to mediate the cel-
ular secretion of -tocopherol (the active form of vitamin
with antioxidant properties) [29]. Thus, it might be pos-
ible that subjects carrying the 2706A allele are more
rotected against lipoprotein oxidation and subsequent risk
f atherosclerosis. Further studies will be necessary to con-
rm this hypothesis. This protective effect also seemed
o be more signiﬁcant in diabetic patients than in those
ithout diabetes (OR 0.53, p = 0.007 vs OR 0.75, p = 0.35).
his result may be explained by the fact that impaired
BCA1 may play a role in the cardiovascular disease that
s the major cause of morbidity and mortality in both type
and type 2 diabetes [33—35]. In fact, two features of
iabetes are elevated glucose and fatty acids [36,37]. It
as reported that the reactive carbonyls glyoxal and gly-
oaldehyde, induced by prolonged hyperglycaemia [38,39],
cutely and severely impair the ABCA1 pathway in cultured
acrophages, presumably by directly damaging the ABCA1
rotein. In addition, fatty acids destabilize the ABCA1 pro-
ein by activating a signalling pathway that phosphorylates
BCA1 and enhances its degradation [40—43].
In our study, in haplotype analysis, after adjustment of
he confounding variables, the most protective (AAGC) hap-
otype was associated with a decreased risk of signiﬁcant
tenosis (OR 0.5, p = 0.048), with a 33% decreased risk of
ypoHDLaemia and a 36% decreased risk of hypoApoAI. We
lso showed that the (GGAT) haplotype increased risk of
igniﬁcant stenosis (OR 1.26, p = 0.025), hypoHDLaemia (OR
.26, p = 0.36) and hypoApoA1 (OR 0.7, p = 0.060).
Some limitations should be noted in our study. Only four
olymorphisms in the ABCA1 gene were studied. It is pos-
ible that other single nucleotide polymorphisms in the
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[36
ene might have more potent associations with HDL-C or
ubclinical atherosclerosis, or that haplotype analysis with
dditional genotyping might increase the power to ﬁnd these
otential associations. Additionally, the size of the study
opulation may have limited our power to perform haplo-
ype and interaction analyses.
In conclusion, we showed that only the A allele of
he G2706A polymorphism seemed to be associated with a
educed risk of signiﬁcant stenosis without important mod-
ﬁcation of serum HDL-C concentration, and that it appears
o be more protective for smokers and diabetic patients.
e found that (AAGC) is a protective haplotype whereas
GGAT) is associated with an atherogenic effect in a Tunisian
opulation.
onﬂict of interest statement
one.
cknowledgements
e are especially grateful to the study participants. We
cknowledge the excellent technical assistance of members
f the Biochemistry and Cardiology Departments of Sahloul
niversity Hospital.
unding: This study was supported by grants from the
unisian Ministry of Higher Education, Scientiﬁc Research
nd Technology and the Tunisian Ministry of Health (UR
8/04); without their extremely generous and strong sup-
ort, this study could not have been undertaken.
eferences
[1] Miller GJ, Miller NE. Plasma-high-density-lipoprotein concen-
tration and development of ischaemic heart-disease. Lancet
1975;1:16—9.
[2] Assmann G, Nofer JR. Atheroprotective effects of high-density
lipoproteins. Annu Rev Med 2003;54:321—41.
[3] Attie AD, Kastelein JP, Hayden MR. Pivotal role of ABCA1 in
reverse cholesterol transport inﬂuencing HDL levels and sus-
ceptibility to atherosclerosis. J Lipid Res 2001;42:1717—26.
[4] Luciani MF, Denizot F, Savary S, et al. Cloning of two novel
ABC transporters mapping on human chromosome 9. Genomics
1994;21:150—9.
[5] Langmann T, Klucken J, Reil M, et al. Molecular cloning of the
human ATP-binding cassette transporter 1 (hABC1): evidence
for sterol-dependent regulation in macrophages. Biochem Bio-
phys Res Commun 1999;257:29—33.
[6] Schaefer EJ, Lamon-Fava S, Ordovas JM, et al. Factors asso-
ciated with low and elevated plasma high density lipoprotein
cholesterol and apolipoprotein A-I levels in the Framingham
Offspring Study. J Lipid Res 1994;35:871—82.
[7] Burris TP, Eacho PI, Cao G. Genetic disorders associated with
ATP binding cassette cholesterol transporters. Mol Genet Metab
2002;77:13—20.
[8] Brunham LR, Singaraja RR, Hayden MR. Variations on a gene:
rare and common variants in ABCA1 and their impact on
HDL cholesterol levels and atherosclerosis. Annu Rev Nutr
2006;26:105—29.
[9] Cenarro A, Artieda M, Castillo S, et al. A common variant in the
ABCA1 gene is associated with a lower risk for premature coro-
[J. Rejeb et al.
nary heart disease in familial hypercholesterolaemia. J Med
Genet 2003;40:163—8.
10] Singaraja RR, Brunham LR, Visscher H, et al. Efﬂux and
atherosclerosis: the clinical and biochemical impact of vari-
ations in the ABCA1 gene. Arterioscler Thromb Vasc Biol
2003;23:1322—32.
11] Zwarts KY, Clee SM, Zwinderman AH, et al. ABCA1 regula-
tory variants inﬂuence coronary artery disease independent
of effects on plasma lipid levels. Clin Genet 2002;61:
115—25.
12] Rejeb J, Omezzine A, Rebhi L, et al. Association of the
cholesteryl ester transfer protein Taq1 B2B2 genotype with
higher high-density lipoprotein cholesterol concentrations and
lower risk of coronary artery disease in a Tunisian population.
Arch Cardiovasc Dis 2008;101:629—36.
13] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the
concentration of low-density lipoprotein cholesterol in plasma,
without use of the preparative ultracentrifuge. Clin Chem
1972;18:499—502.
14] Miller SA, Dykes DD, Polesky HF. A simple salting out procedure
for extracting DNA from human nucleated cells. Nucleic Acids
Res 1988;16:1215.
15] Yoo J, Seo B, Kim Y. SNPAnalyzer: a web-based integrated work-
bench for single-nucleotide polymorphism analysis. Nucleic
Acids Res 2005; 33:W483—8.
16] Benton JL, Ding J, Tsai MY, et al. Associations between two
common polymorphisms in the ABCA1 gene and subclinical
atherosclerosis: Multi-Ethnic Study of Atherosclerosis (MESA).
Atherosclerosis 2007;193:352—60.
17] Clee SM, Zwinderman AH, Engert JC, et al. Common genetic
variation in ABCA1 is associated with altered lipoprotein lev-
els and a modiﬁed risk for coronary artery disease. Circulation
2001;103:1198—205.
18] Frikke-Schmidt R, Nordestgaard BG, Jensen GB, et al. Genetic
variation in ABCA1 predicts ischemic heart disease in the gen-
eral population. Arterioscler Thromb Vasc Biol 2008;28:180—6.
19] Woll PS, Hanson NQ, Arends VL, et al. Effect of two common
polymorphisms in the ATP binding cassette transporter A1 gene
on HDL-cholesterol concentration. Clin Chem 2005;51:907—9.
20] Yamakawa-Kobayashi K, Yanagi H, Yu Y, et al. Associa-
tions between serum high-density lipoprotein cholesterol or
apolipoprotein AI levels and common genetic variants of the
ABCA1 gene in Japanese school-aged children. Metabolism
2004;53:182—6.
21] Jensen MK, Pai JK, Mukamal KJ, et al. Common genetic
variation in the ATP-binding cassette transporter A1, plasma
lipids, and risk of coronary heart disease. Atherosclerosis 2007;
195:e172—80.
22] Kyriakou T, Hodgkinson C, Pontefract DE, et al. Genotypic
effect of the -565C>T polymorphism in the ABCA1 gene pro-
moter on ABCA1 expression and severity of atherosclerosis.
Arterioscler Thromb Vasc Biol 2005;25:418—23.
23] Lutucuta S, Ballantyne CM, Elghannam H, et al. Novel polymor-
phisms in promoter region of atp binding cassette transporter
gene and plasma lipids, severity, progression, and regression
of coronary atherosclerosis and response to therapy. Circ Res
2001;88:969—73.
24] Saleheen D, Khanum S, Haider SR, et al. A novel haplotype in
ABCA1 gene effects plasma HDL-C concentration. Int J Cardiol
2007;115:7—13.
25] Takagi S, Iwai N, Miyazaki S, et al. Relationship between
ABCA1 genetic variation and HDL cholesterol level in subjects
with ischemic heart diseases in Japanese. Thromb Haemost
2002;88:369—70.
26] Tregouet DA, Ricard S, Nicaud V, et al. In-depth haplotype anal-
ysis of ABCA1 gene polymorphisms in relation to plasma ApoA1
levels and myocardial infarction. Arterioscler Thromb Vasc Biol
2004;24:775—81.
[[
[
[
[
[
[
[ABCA1 polymorphisms and coronary artery disease
[27] Wang J, Burnett JR, Near S, et al. Common and rare ABCA1
variants affecting plasma HDL cholesterol. Arterioscler Thromb
Vasc Biol 2000;20:1983—9.
[28] Sandhofer A, Iglseder B, Kaser S, et al. The inﬂuence of two
variants in the adenosine triphosphate-binding cassette trans-
porter 1 gene on plasma lipids and carotid atherosclerosis.
Metabolism 2008;57:1398—404.
[29] Andrikovics H, Pongracz E, Kalina E, et al. Decreased frequen-
cies of ABCA1 polymorphisms R219K and V771M in Hungarian
patients with cerebrovascular and cardiovascular diseases.
Cerebrovasc Dis 2006;21:254—9.
[30] Cuchel M, Rader DJ. Macrophage reverse cholesterol trans-
port: key to the regression of atherosclerosis? Circulation
2006;113:2548—55.
[31] Francone OL, Royer L, Boucher G, et al. Increased cholesterol
deposition, expression of scavenger receptors, and response
to chemotactic factors in Abca1-deﬁcient macrophages. Arte-
rioscler Thromb Vasc Biol 2005;25:1198—205.
[32] Aiello RJ, Brees D, Bourassa PA, et al. Increased atheroscle-
rosis in hyperlipidemic mice with inactivation of ABCA1 in
macrophages. Arterioscler Thromb Vasc Biol 2002;22:630—7.
[33] Haghpassand M, Bourassa PA, Francone OL, et al. Mono-
cyte/macrophage expression of ABCA1 has minimal contribu-
tion to plasma HDL levels. J Clin Invest 2001;108:1315—20.
[34] Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy
and carotid intima-media thickness in type 1 diabetes mellitus.
N Engl J Med 2003;348:2294—303.
[537
35] Ruderman NB, Williamson JR, Brownlee M. Glucose and dia-
betic vascular disease. FASEB J 1992;6:2905—14.
36] Reaven GM, Hollenbeck C, Jeng CY, et al. Measurement of
plasma glucose, free fatty acid, lactate, and insulin for 24 h in
patients with NIDDM. Diabetes 1988;37:1020—4.
37] Seigneur M, Freyburger G, Gin H, et al. Serum fatty acid pro-
ﬁles in type I and type II diabetes: metabolic alterations of
fatty acids of the main serum lipids. Diabetes Res Clin Pract
1994;23:169—77.
38] Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in
atherogenesis. Free Radic Biol Med 2000;28:1708—16.
39] Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal,
methylglyoxal and 3-deoxyglucosone in the glycation of pro-
teins by glucose. Biochem J 1999;344 (Pt 1):109—16.
40] Wang Y, Kurdi-Haidar B, Oram JF. LXR-mediated activation
of macrophage stearoyl-CoA desaturase generates unsatu-
rated fatty acids that destabilize ABCA1. J Lipid Res 2004;45:
972—80.
41] Wang Y, Oram JF. Unsaturated fatty acids inhibit cholesterol
efﬂux from macrophages by increasing degradation of ATP-
binding cassette transporter A1. J Biol Chem 2002;277:5692—7.
42] Wang Y, Oram JF. Unsaturated fatty acids phosphorylate and
destabilize ABCA1 through a phospholipase D2 pathway. J Biol
Chem 2005;280:35896—903.
43] Wang Y, Oram JF. Unsaturated fatty acids phosphorylate and
destabilize ABCA1 through a protein kinase C delta pathway. J
Lipid Res 2007;48:1062—8.
